CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.

Roya BehrouziAnne C ArmstrongSacha J Howell

Published in: Breast cancer research and treatment (2023)

In this retrospective study, patients with ER+/HER2- ABC and IVC/VC treated with CDK4/6i had a significantly better survival compared to those treated with weekly paclitaxel. Further prospective studies that minimise possible selection bias are recommended.

Keyphrases

cell cycle
endoplasmic reticulum
estrogen receptor
breast cancer cells
public health
inferior vena cava
newly diagnosed
metabolic syndrome
case control
combination therapy
chemotherapy induced
young adults
skeletal muscle
pulmonary embolism
smoking cessation